University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Food and Drug Administration Papers

U.S. Department of Health and Human Services

2017

The impact of the boxed warning on the duration of
use for depot medroxprogesterone acetate
Efe Eworuke
Food and Drug Administration, efe.eworuke@fda.hhs.gov

Joo-Yeon Lee
Food and Drug Administration

Lisa Soule
Food and Drug Administration

Vaishali Popat
Food and Drug Administration

David G. Moeny
Food and Drug Administration

Follow this and additional works at: http://digitalcommons.unl.edu/usfda
Part of the Dietetics and Clinical Nutrition Commons, Health and Medical Administration
Commons, Health Services Administration Commons, Pharmaceutical Preparations Commons, and
the Pharmacy Administration, Policy and Regulation Commons
Eworuke, Efe; Lee, Joo-Yeon; Soule, Lisa; Popat, Vaishali; and Moeny, David G., "The impact of the boxed warning on the duration of
use for depot medroxprogesterone acetate" (2017). Food and Drug Administration Papers. 25.
http://digitalcommons.unl.edu/usfda/25

This Article is brought to you for free and open access by the U.S. Department of Health and Human Services at DigitalCommons@University of
Nebraska - Lincoln. It has been accepted for inclusion in Food and Drug Administration Papers by an authorized administrator of
DigitalCommons@University of Nebraska - Lincoln.

pharmacoepidemiology and drug safety 2017; 26: 827–836
Published online 23 May 2017 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/pds.4227

ORIGINAL REPORT

The impact of the boxed warning on the duration of use for depot
medroxprogesterone acetate
Efe Eworuke1*

, Joo-Yeon Lee2, Lisa Soule3, Vaishali Popat4 and David G. Moeny1

1

Division of Epidemiology II, Ofﬁce of Pharmacovigilance and Epidemiology, Ofﬁce of Surveillance and Epidemiology, Center for Drug
Evaluation and Research, Food and Drug Administration, Silver Spring, MA, USA
2
Division of Biometrics VII, Ofﬁce of Biostatistics, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring,
MA, USA
3
Division of Bone, Reproductive, and Urologic Products, Ofﬁce of New Drugs, Center for Drug Evaluation and Research, Food and Drug
Administration, Silver Spring, MA, USA
4
Ofﬁce of New Drugs, Immediate Ofﬁce, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MA, USA

ABSTRACT
Objective The objective of this study was to examine the impact of the Food and Drug Administration’s boxed warning on the utilization
of depot medroxyprogesterone (DMPA).
Methods From the IMS Lifelink data (2001–2009), we identiﬁed DMPA and oral combined hormonal contraceptive (CHC) users without
a prescription claim 6 months before and after the ﬁrst and last claim. Episodes were deﬁned as all contiguous claims with no more than 90day DMPA or 30-day CHC between claims. Days’ supply (CHC) and 90-day duration (DMPA) was used to determine episodes. We used
interrupted time series to evaluate changes in the mean episode length and proportion of episodes >2 years before and after the Food and
Drug Administration’s November 2004 boxed warning. Stratiﬁed analyses by birth cohort were conducted.
Results From 2001 to 2009, 126 528 DMPA and 651 356 CHC episodes were used for segmented regression. For the DMPA cohort, there
was an immediate decline in the mean duration ( 34.7 days [conﬁdence interval: 45.4 to 24.1]) and episodes >2 years ( 1.9%
[conﬁdence interval: 2.9% to 1.1%]) after the boxed warning. We did not observe any change in mean duration or episodes >2 years
for the CHC cohort. The largest declines in mean duration and proportion >2 years were seen with the oldest women.
Conclusion We observed a modest decline in the mean duration and episodes >2 years for DMPA use immediately after the boxed warning not
observed among CHC users. In the stratiﬁed analysis, we saw declines in the duration of use >2 years in all age groups, except adolescents who
continue to use DMPA for longer than 2 years. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
key words—boxed warning; depot medroxyprogesterone; interrupted time series; trends; pharmacoepidemiology
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INTRODUCTION
The US Food and Drug Administration (FDA)
approved depot medroxyprogesterone acetate (DMPA;
Depo-Provera contraceptive injection) in October
19921 and subcutaneous depot medroxyprogesterone
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(depo-subQ provera 104) in October 20042 for the
prevention of pregnancy. Depo-subQ provera 104 is
also approved for management of endometriosisassociated pain. DMPA results in decreased estrogen
production because of its inhibition of pituitary
gonadotropin secretion.3 Decreased estrogen production is particularly concerning because it is associated
with decreases in bone mineral density (BMD). Shortly
after approval of DMPA in 1992, postmarketing
studies4–11 in both adult and adolescent women
suggested loss of BMD with DMPA use. Longer
duration of treatment and smoking tobacco were
associated with slower recovery of BMD following
the last DMPA use.12 Another study6 suggested that
BMD levels at the femoral neck and hip showed slower
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recovery compared with levels at the lumbar spine after
treatment discontinuation. In 2004, the FDA approved a
boxed warning to communicate these risks. Boxed
warnings are used when there is a serious adverse
reaction (in this case, loss of BMD) that can be
prevented or reduced in frequency or severity by
appropriate use of the drug (i.e., limiting duration of
use) to ensure safe use. The initial boxed warning in
2004 and its subsequent revision in 2010 were based
on FDA’s review of clinical data submitted by the
sponsor, the ﬁndings of the postmarketing study13 and
another observational study.14 The current boxed
warning states that DMPA may result in signiﬁcant
BMD loss, which is greater with increasing duration
of use and may not be completely reversible, and that
it is not known if contraceptive use during adolescence
or early adulthood, a critical period of bone accretion,
will reduce peak bone mass and increase the risk for
osteoporotic fracture later in life. And lastly, labeling
states that DMPA injection should only be used as
long-term birth control (i.e., longer than 2 years) if other
methods are inadequate.
Shortly after the boxed warning, several public
organizations
including
the
World
Health
Organization,15 the American College of Obstetricians
and Gynecologists,16 and the Society of Adolescent
Medicine17 indicated that skeletal health concerns
should not restrict DMPA use including duration of
use. With conﬂicting guidance from professional
organizations and from the FDA, it is unknown how
prescribers would react to the boxed warning.
Currently, evaluation of the impact of the boxed
warning and published guidelines on DMPA prescribing is limited to a Florida survey18 conducted
among obstetrician-gynecologists. The study revealed
that 46% of these physicians place a 2-year time limit
on DMPA use, and more than half of the respondents
report that they instituted this time limit because of
the boxed warning. Small sample size, volunteer bias,
recall bias, and limited generalizability of the study
population preclude generalizing these survey ﬁndings
to other practitioners in the USA. With several public
organizations releasing statements against the warning,
coupled with existing evidence limited to only one
survey, we sought to examine changes in the trends of
DMPA use because of the boxed warning issued in
November 2004 in a large commercial database.
METHODS
Data source
We obtained data from the IMS Health LifeLink
dataset. The dataset consists of fully adjudicated
Published 2017. This article is a U.S. Government work and
is in the public domain in the USA.

medical, pharmacy, and enrollment information from
over 100 managed care plans. Key data elements
include costs, diagnoses, prescription drugs, services
rendered across all sites of care, and patient demographic information. IMS LifeLink data provide
patient-level data for over 65.8 million individuals
for health services initiated across the USA.
Study population
We identiﬁed DMPA users as patients from the 2001–
2013 IMS LifeLink dataset, who received a
prescription for subcutaneous or intramuscular DMPA
through a pharmacy, those with a procedure code for
the administration of DMPA at the physician’s ofﬁce
(J1051, J1055, J1056, J1050), or patients with a
procedure code for the administration of an unclassiﬁed drug (J3490) with a corresponding prescription
claim for DMPA on the same day. We refer to this
sample as DMPA users. From the source population,
we identiﬁed users of oral formulations of combined
hormonal contraceptives (CHCs) as an active comparator. Patients with a pharmacy prescription claim
for any oral CHC were included. We excluded from
the CHC population women who used DMPA during
the study period to select women who were less likely
to switch from DMPA to CHC. We refer to this sample
as CHC users.
To create the ﬁnal DMPA study population, we
restricted DMPA users to patients with year of birth
1963–2001 (representative of child-bearing age), with
at least 6 months of continuous enrollment prior to the
ﬁrst DMPA medical or pharmacy claim and at least
6 months of continuous enrollment after the last
DMPA claim. The same enrollment criteria were used
to create the ﬁnal CHC study population.
Episode construction
All pharmacy and medical claims for DMPA between
the ﬁrst and last DMPA claims were retrieved and
used to construct the episodes of DMPA use. Each
episode began with the ﬁrst DMPA claim or a
subsequent DMPA claim and included all DMPA
claims that had no more than a 90-day gap period
between claims. The duration of DMPA exposure
following administration was deﬁned as 90 days in
accordance with the product labeling. Therefore, the
presence of another claim before the 90-day deﬁned
duration resulted in an overlap between prescription
claims, which was excluded from the analysis. This
criterion was applied because we assumed data entry
errors for earlier injection administration before the
90-day period. In a sensitivity analysis, we changed
Pharmacoepidemiology and Drug Safety, 2017; 26: 827–836
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the 90-day gap between claims to 75 and 105 days to
reﬂect early or later injection as observed in clinical
practice. For the CHC episodes, we relied on the
pharmacy-calculated days’ supply to determine the
duration of episode. Given that overlap days for the
CHC user increased exposure time, overlap days were
added to the episode length and not excluded. The
length of the episode duration (in days) was calculated
for all episodes constructed in both cohorts. After the
episodes were created, we mapped all the episodes
by calendar month. In each calendar month, the
lengths of all episodes were used to calculate the mean
episode length in days (we refer to this as mean
duration) for the month and the proportion of patients
(expressed as percent) who have episodes of use
greater than 730 days (we refer to this as proportion
>2 years). We used only the ﬁrst DMPA and CHC
episodes and obtained both the mean duration and
proportion >2 years for each start month of DMPA
or CHC prescription.
ANALYSIS
Interrupted time series
Interrupted time series (ITS) was applied to assess the
impact of the boxed warning issued in November
2004. Two endpoints, which are the mean duration
and the proportion >2 years, were analyzed separately
in terms of monthly trends and change in trend before
and after the boxed warning. To ensure that the trends
observed using the DMPA cohort were not attributed
to study sample deﬁnitions and to conﬁrm that
ﬁndings were unique to DMPA, we conducted the
same analyses among CHC users. The ITS design with
a control group is a valid quasi-experimental study
able to estimate intervention effects (e.g., policy
implementation) in non-randomized settings.19 In
contrast to pre-post designs, ITS uses multiple
assessments of the outcome variable before and after
the intervention, thus reducing the threats (such as history
and maturation) to the internal validity of the study.19
The data for ITS analysis were restricted to July
2001 (because of limited data from January 2001 to
June 2001) to December 2009 (to assure ample
follow-up time). In the ﬁnal model, the baseline trend
estimated the trend for mean monthly duration or
proportions before the boxed warning; level change
estimated the change immediately after the warning,
and trend change estimated the change in slope (trend)
before and after the boxed warning. Stratiﬁed analyses
by birth year strata (1963–1972, 1973–1977, 1978–
1982, 1983–1987, >1987) and concurrent CHC use
were also conducted to examine differences in trends
Published 2017. This article is a U.S. Government work and
is in the public domain in the USA.
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by strata. All regressions were performed using the
PROC AUTOREG procedure within SAS version 9.4
(SAS Institute, Inc., Cary, NC, USA). Autocorrelation
between error terms was assessed using the Durbin–
Waston test statistic. Models were assessed by looking
at various model diagnostics such as residual plots and
autocorrelation factor (ACF)/partial autocorrelation
factor (PACF) function. In a sensitivity analysis, we
excluded all episodes that were initiated prior to 1
January 2004 and ended between 1 January 2004 and
31 December 2004 to exclude episodes possibly
terminated because of the implementation of the boxed
warning. The study was exempted from review by the
FDA Research Involving Human Subjects committee
under 45 CFR 46 101(b)(4).
RESULTS
We identiﬁed 659 783 DMPA users from January
2001 to December 2013. Further restrictions requiring
enrollment information in the 6 months prior to ﬁrst
DMPA use and continuous enrollment after last
DMPA use resulted in a sample of 191 927 users.
Finally, we restricted to women born between 1963
and 2001 to increase the likelihood that DMPA use
was indicative of contraception (Figure 1). The same
criteria were applied to the CHC cohort. The ﬁnal
sample included 517 801 DMPA claims for 179 108
women and 5 989 949 CHC claims for 845 189
women. This created 203 477 DMPA and 1 309 298
CHC episodes from the ﬁnal sample. The ITS analysis
(analytical cohort) included a total of 126 528 and
651 356 DMPA and CHC new users, respectively,
between July 2001 and December 2009.
A summary of selected characteristics summarized
in Table 1 contrasts the DMPA and CHC users for
the analytical cohort. DMPA users were younger,
more likely born after 1987 (25.1%) compared with
CHC users who were older, more likely born between
1963 and 1972 (24.3%). The regional distribution for
DMPA and CHC users was similar. Most of the
women were in the Midwest region followed by the
South region for both cohorts. We observed only a
small proportion (10.2%) of DMPA users concurrently
used a CHC during their DMPA use compared with
those who used a CHC before ﬁrst DMPA use
(15.7%) or after last DMPA use (20.1%). Further
evaluation of the 10.3% of overlapping episodes
revealed that 84.7% (n = 15; 271 episodes) had a
CHC claim that occurred within 30 days of the episode
end date (n = 13; 972 episodes) or episode start date
(n = 2; 183 episodes) suggesting a possible switch at
the beginning or end of the DMPA episode. These data
Pharmacoepidemiology and Drug Safety, 2017; 26: 827–836
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Figure 1. Flow chart deriving the ﬁnal study cohorts. DMPA, depot medroxyprogesterone acetate; CHC, combined hormonal contraceptive

Table 1. Selected characteristics of DMPA and CHC new users
DMPA new
users
Characteristic
Birth year
1963–1972
1973–1977
1978–1982
1983–1987
>1987
Region
East
Midwest
South
West
CHC use during ﬁrst
DMPA episode
CHC use in the 6 months
prior to ﬁrst DMPA use
CHC use in the 6 months
after last DMPA use

CHC new
users

n = 126 528

%

n = 651 356

%

24 362
17 643
23 799
28 166
32 302

19.3
13.9
18.8
22.3
25.6

156 856
108 931
123 717
132 423
127 694

24.1
16.7
19.0
20.3
19.7

23 455
48 451
32 780
21 842
12 972

18.5
38.3
25.9
17.3
10.3

128 450
232 805
176 891
113 210
NA

19.7
35.7
27.2
17.4
NA

19 915

15.7

NA

NA

26 027

20.6

NA

NA

DMPA, depot medroxyprogesterone acetate; CHC, combined hormonal
contraceptive; NA, not applicable.

indicate that while there may be possible overlapping
DMPA and CHC use, the probability of this occurrence is quite low.
The number of new users each month increased over
time for both the DMPA and CHC cohorts and
declined in the ﬁnal months of the study period
(Figure 2a). Both cohorts displayed similar time trends
over time with a distinct increase in the number of new
users in June 2003. The same spike in the number of
new users was also observed when we examined the
number of users each month (Figure 2b).
Published 2017. This article is a U.S. Government work and
is in the public domain in the USA.

Examining the duration of use, we found that the
monthly mean duration ( 34.7 days [conﬁdence
interval (CI): 45.4 to 24.1; p < 0.0001]) and the
proportion >2 years ( 1.9% [CI: 2.9 to 1.1;
p < 0.0001]) signiﬁcantly reduced right after the
boxed warning for the DMPA cohort only (Figure 3a
and b). We did not observe a level change after the
warning in the CHC cohort for both mean duration
and proportion >2 years, although the trend change
was signiﬁcant for both the mean duration and
proportion >2 years for both cohorts (Table 2).
For the stratiﬁed analysis by birth cohort, we
excluded 282 and 1914 DMPA and CHC users,
respectively, because the estimated age at index date
was <11 years. Examining DMPA utilization by birth
cohorts suggests differences by age. Prior to the boxed
warning, all birth cohorts for DMPA users exhibited
signiﬁcant increasing baseline trend for the monthly
mean duration (Table 3). Using the proportion
>2 years as the endpoint, we also observed similar
baseline trends across birth cohorts except for the
post-1987 birth cohort, which exhibited a signiﬁcant
“downward” baseline trend prior to the boxed warning
( 0.6% [CI: 0.4% to 0.8%]). The baseline trend for
monthly mean duration for the CHC birth cohorts was
not statistically signiﬁcant except for the 1978–1982
and post-1987 birth cohorts. Although we found
statistically signiﬁcant increases in the baseline trends
for proportion >2 years among the CHC birth cohorts
prior to the boxed warning, the magnitude of the
slopes was smaller than that observed in the DMPA
birth cohorts (Table 3).
Except for the post-1987 and 1978–1982 birth
cohorts, we observed signiﬁcant declines in the mean
Pharmacoepidemiology and Drug Safety, 2017; 26: 827–836
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Figure 2. (a) Depot medroxyprogesterone acetate (DMPA) and combined hormonal contraceptive (CHC) new users each month over the study period. (b)
Proportion of episodes >730 days* of monthly DMPA and CHC users per eligible population each month over the study period. The numerator is the number
of new users in the month of interest, while the denominator includes the number of women included in the study based on cohort entry requirements. At the
initial study months, the denominator comprises mainly of new users (large percent of new users per eligible population). However over time, the denominator
*
comprises of prevalent users with a steady rate of new users. Calculated as the number of subjects >730 days/total number of subjects who initiated DMPA in
each month. [Colour ﬁgure can be viewed at wileyonlinelibrary.com]

duration and proportion >2 years for all DMPA birth
cohorts immediately after the boxed warning (level
change) (Table 3). For the >1987 cohort, we observed
a non-signiﬁcant increase in level change for
proportion >2 years (3.7% [CI: 8.6% to 1.2%])
and a decline (non-signiﬁcant) for 1978–1982 birth
cohort ( 1.2% [CI: 2.5% to 0.1%]) (Table 3).
Statistical signiﬁcance was not achieved in the CHC
stratiﬁed birth cohorts, except for 1983–1987 birth
cohort (Table 3). For the DMPA birth cohorts, the
magnitude of the level change also varied by birth
cohort, the oldest (1963–1972) ( 55.0 days [CI:
35.7 to 74.4]) and youngest women (post-1987)
( 43.1 days [CI: 24.9 to 61.3]) exhibited the
largest decline. Except for the post-1987 birth cohort,
the mean duration “level change” observed in the
Published 2017. This article is a U.S. Government work and
is in the public domain in the USA.

DMPA birth cohorts accompanied a decline in percent
of episodes >2 years. Older women (1963–1972)
( 3.7% [CI: 2.5% to 4.8%]) exhibited the largest
decline in magnitude. For the youngest birth cohort,
although there was a decline in the mean duration,
we observed no level change for proportion >2 years
(Table 3).
The difference in the slopes before and after the
boxed warning (trend change) for both the mean
duration and proportion >2 years was signiﬁcant in
all DMPA birth cohorts. The trends in the CHC birth
cohorts were less consistent; some of the birth cohorts
(1963–1972 and 1983–1987) showed no difference in
monthly mean duration trend pre-boxed and postboxed warning, while the remaining CHC birth
cohorts had a signiﬁcant trend change (Table 3).
Pharmacoepidemiology and Drug Safety, 2017; 26: 827–836
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Figure 3. (a) Mean duration of episodes of use (in days) over the study period. For all episodes initiated in the respective month, the mean duration of episode
was calculated for both Depot medroxyprogesterone acetate (DMPA) and combined hormonal contraceptive (CHC) cohorts. Y-axis represents the calculated
mean for each calendar month, and X-axis represents the number of months since July 2001 till December 2009. (b) Proportion of episodes >730 days* over
the study period. For all episodes initiated in the respective month, the proportion of episode with days >730 of all episodes that month was calculated for both
DMPA and CHC cohorts. Y-axis represents the calculated mean for each calendar month, and X-axis represents the number of months since July 2001 till
December 2009. *Calculated as the number of subjects >730 days/total number of subjects who initiated DMPA in each month 100. [Colour ﬁgure can be
viewed at wileyonlinelibrary.com]

Table 2. Interrupted time series analysis and conﬁdence intervals for DMPA and CHC new users
Variable

Estimate

LCL

Model
Model 1 (mean in days)

Model 2 (proportions*)

UCL

p-value

Estimate

DMPA
Intercept
Baseline trend
Level change
Trend change
Intercept
Baseline trend
Level change
Trend change

208.9
1.9
34.7
2.3
3.1
0.1
1.9
0.1

200.8
1.5
45.4
2.7
2.4
0.08
2.9
0.2

LCL

UCL

p-value

203.8
0.6
5.9
0.2
5.0
0.07
0.3
0.04

<.0001
0.0985
0.4754
0.0016
<.0001
0.0003
0.3576
<.0001

CHC
217.1
2.2
24.1
1.9
3.8
0.2
1.1
0.09

<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001

196.5
0.27
3.4
0.6
4.5
0.04
0.3
0.07

189.3
0.05
12.6
0.96
3.97
0.02
0.94
0.09

DMPA, depot medroxyprogesterone acetate; CHC, combined hormonal contraceptive; LCL, lower conﬁdence interval; UCL, upper conﬁdence interval.
Baseline trend represents the estimated trend for mean monthly duration or proportions before the boxed warning; level change represents the estimated change
immediately after the warning, and trend change represents the estimated change in slope (trend) before and after the boxed warning.
*Calculated as the number of subjects >730 days/total number of subjects who initiated DMPA in each month multiplied by 100.

Published 2017. This article is a U.S. Government work and
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211 (225.8 to 196.3)
215.7 (226.7 to 204.7)
193.5 (205.1 to 181.9)
230.2 (243.7 to 216.7)
235 (249 to 220.9)

1963–1972
1973–1977
1978–1982
1983–1987
>1987

208.8 (219.5 to 198)
192.2 (200.1 to 184.2)
166.6 (174 to 159.3)
214.8 (225.1 to 204.5)
153.2 (168.8 to 137.7)

CHC
2.3
1.3
1.7
0.9
2.8

(3 to 1.7)
(1.8 to 0.8)
(2.2 to 1.2)
(1.5 to 0.3)
(3.5 to 2.2)

DMPA

3.7
1.9
1.2
2.5
3.7

55
29.8
20.2
33.9
43.1

35.7 to 74.4)
15.3 to 44.2)
5.1 to 35.2)
16.8 to 51.1)
24.9 to 61.3)

( 2.5 to 4.8)
( 0.5 to 3.2)
( 2.5 to 0.1)
( 1.1 to 3.9)
(8.6 to 1.2)

(
(
(
(
(

DMPA

0.2
0.7
0
1.1
0.3

3
3.4
1.8
17.2
19.2

Level change

(0.7 to 1.1)
( 0.1 to 1.3)
(0.7 to 0.7)
( 0.1 to 2.1)
(0.9 to 1.6)

(10.8 to 16.7)
(7 to 13.7)
(11.3 to 7.7)
( 4.1 to 30.3)
( 39.6 to 1.2)

CHC

2.4
1.3
1.5
0.6
3.3

to
to
to
to
to

3.9)
2.4)
2.6)
2)
4.6)
0.2 ( 0.1 to 0.2)
0.1 (0 to 0.1)
0.1 (0 to 0.2)
0.1 (0 to 0.2)
0.5 (0.8 to 0.2)

3.2 (
1.8 (
2.1 (
1.3 (
4(

DMPA

(0.3 to 0.7)
( 0.4 to 1.2)
( 1 to 1.8)
( 1 to 0.1)
( 2.5 to 4)

CHC

0.1 (0 to 0.1)
0.1 ( 0.1 to 0.1)
0.1 ( 0.1 to 0.1)
0 (0 to 0)
0.1 (0 to 0.2)

0.2
0.8
1.4
0.5
3.3

Trend change

DMPA, depot medroxyprogesterone acetate; CHC, combined hormonal contraceptive.
Proportions were calculated as the number of subjects >730 days/total number of subjects who initiated DMPA in each month 100.
Baseline trend represents the estimated trend for mean monthly duration or proportions before the boxed warning; level change represents the estimated change immediately after the warning, and trend
change represents the estimated change in slope (trend) before and after the boxed warning.

0 (0.1 to 0)
0.1 (0.1 to 0)
0.1 (0.1 to 0)
0 (0 to 0)
0.1 (0.1 to 0.1)

to 0.7)
to 0.1)
to 0.6)
to 0.4)
to 2)

CHC
0.2 (0.2
0.3 (0.6
0.9 (1.3
0 (0.5
2.7 (3.4

Baseline trend

Model parameter estimates using monthly proportion of episodes >730 days (in percent)
1963–1972
3.2 (4.1 to 2.4)
4.9 (5.6 to 4.2)
0.2 (0.2 to 0.1)
1973–1977
3.5 (4.6 to 2.5)
3.9 (4.4 to 3.4)
0.1 (0.1 to 0)
1978–1982
2.3 (3.3 to 1.3)
3.4 (3.9 to 2.9)
0.1 (0.1 to 0.1)
1983–1987
3.4 (4.5 to 2.3)
5.9 (6.8 to 5)
0.1 (0.1 to 0.1)
>1987
27.5 (33.8 to 21.3)
4.6 (5.8 to 3.4)
0.6 ( 0.4 to 0.8)

DMPA

Intercept

Birth Year
Cohort

Model parameter estimates using monthly mean duration (in days)

Table 3. Interrupted time series analysis and conﬁdence intervals for DMPA and CHC new users stratiﬁed by birth year

boxed warning and depot medroxyprogesterone
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percent change in the proportion of episodes >2 years
resulted in similar ﬁndings. Speciﬁcally, for DMPA
users, there was a signiﬁcant decline in level change
for monthly mean duration and proportion >2 years.
On the contrary, the CHC cohort exhibited no level
change in the monthly mean duration and proportions
immediately after boxed warning. The DMPA cohort
also exhibited a signiﬁcant difference in the trend
change post-boxed warning. Among the CHC users,
we also found a signiﬁcant trend change similar to
DMPA users. We were unclear why there would be a
difference in the slopes before and after the boxed
warning for the CHC cohort, given the absence of a
level change. One possible explanation is the decline
in the number of users for both cohorts toward the
end of the study period. It is noteworthy to mention that
our analysis was truncated at December 2009 to reduce
this problem; however, as seen in Figure 2, we begin to
see a drop in sample size prior to December 2009.
Stratiﬁed analyses suggest differences in duration of
use by age. The largest decline in the mean duration in
the DMPA cohort after the implementation of the
boxed warning was observed among the oldest
(1963–1972 birth cohort) and the youngest cohorts
(post-1987 birth cohort). While a similar decrease
was observed with the proportion >2 years for the
older cohort, this trend was not replicated in among
the younger women. The magnitude of level change
also seemed to decrease with decreasing age (Table 3).
These distinct differences by birth cohort may reﬂect
clinical practice decisions; oldest and youngest
patients perceived as having a higher risk of BMD
loss may have been more likely to receive DMPA
for a shorter duration following the warning, hence
the decline in level change and trend change. The
absence of a decline in the proportion of patients with
episodes >730 days for the youngest cohort suggests
that the number of women who received DMPA for
>730 days remained constant during the study period.
While the mean duration is sensitive to any change in
duration, the proportion of episodes >730 days reﬂect

For the stratiﬁed analysis by concurrent CHC status,
DMPA utilization patterns remained the same among
women who used concurrent CHCs during DMPA
episodes and those who did not (Table 4). The
magnitude of level change for mean duration for nonconcurrent DMPA-contraceptive users was smaller
( 18.9; CI: 35.3 to 2.5) compared with concurrent
users ( 36.5; CI: 47.6 to 25.5) (Table 4). Similarly,
baseline trend (non-concurrent: 1.3; concurrent: 1.93)
and trend change (non-concurrent: 1.6; concurrent:
2.4) followed the same pattern. Sensitivity analyses
based on 75 or 105 days between DMPA claims (rather
than 90 days) did not change our results (Appendix).
Other sensitivity analyses, excluding DMPA episodes
initiated before 1 January 2004 and ended between 1
January 2004 and 31 December 2004, also did not
change our study ﬁndings.
DISCUSSION
In our study, we found a signiﬁcant decline in the
monthly mean duration of use and proportion of
patients who have episodes of use greater than 730 days
immediately after the boxed warning for the DMPA
cohort; this was not seen in the CHC cohort. The
observed pattern of utilization was not associated with
a change in the number of users as we found
comparable time trends for monthly new users in both
the DMPA and CHC cohorts with no noticeable change
after the boxed warning. This ﬁnding highlights the
effectiveness of the FDA warning in limiting prolonged
use of DMPA and not necessarily the change in the
number of new users over the study period.
We examined whether prescribers were complying
with the 2-year recommendation using two different
analytical approaches. Using the episode of continuous
use, we ﬁrst assessed whether the mean duration of
episodes changed signiﬁcantly after the boxed
warning. We observed signiﬁcant changes in the mean
duration, which was not found among CHC users. The
analysis of the proportion >2 years examining the

Table 4. Interrupted time series analysis and conﬁdence intervals for DMPA users stratiﬁed by concurrent combined hormonal contraceptive use
Combined hormonal contraceptive (yes)
Model
(Mean in days)

Combined hormonal contraceptive (no)

Variable

Estimate

LCL

UCL

p-value

Estimate

LCL

UCL

p-value

Intercept
Baseline trend
Level change
Trend change

245.6
1.3
18.9
1.6

233.1
0.7
35.3
2.2

258.1
1.8
2.5
0.9

<.0001
<.0001
0.026
<.0001

204.5
1.8
36.5
2.4

196.1
1.5
47.6
2.8

213.0
2.2
25.5
1.9

<.0001
<.0001
<.0001
<.0001

DMPA, depot medroxyprogesterone acetate; LCL, lower conﬁdence interval; UCL, upper conﬁdence interval.
Baseline trend represents the estimated trend for mean monthly duration or proportions before the boxed warning; level change represents the estimated change
immediately after the warning, and trend change represents the estimated change in slope (trend) before and after the boxed warning.
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only changes in use >2 years. This trend may be
explained by published recommendations from the
American Society for Adolescent Medicine.17 It states
that “DMPA duration of use need not be restricted to
2 years in adolescent population.” It is possible that
the observed increased level change after the boxed
warning in the younger patients is reﬂective of these
recommendations. Given the limited sample size for
this subcohort and the absence of the full date of birth
in the data, future studies will be needed to conﬁrm
these trends.
To date, there have been no other studies examining
the impact of the boxed warning on the duration of use
of DMPA. Our study has the following implications:
ﬁrst, use of DMPA is not declining over time. Similar
trends in the rate of new users in both the DMPA and
CHC cohorts observed suggest that the initiation of
DMPA has not changed. Second, amidst conﬂicting
guidance, some prescribers and patients in the USA
have adopted the 2-year time limit for DMPA use.
Third, the analysis stratiﬁed by birth cohort suggests
that not all patients have adopted the 2-year limit.
Speciﬁcally, the youngest patients deemed to be at a
higher risk for bone mineral loss, continue DMPA
for longer than 2 years. Future studies would need to
conﬁrm these ﬁndings and the resulting effect of
long-term DMPA use among adolescents.
Our study has several strengths. First, the ITS is the
strongest quasi-experimental design to evaluate
longitudinal effects of time-delimited interventions.19
The model allows for estimating in statistical terms
the impact of an intervention on an outcome of interest.
Second, our study incorporated a control group of CHC
users in the design to assure that the observed changes
are related to the intervention of interest and not due
to other factors associated with drug utilization in the
study dataset. Lastly, our analysis was also able to
examine DMPA utilization in a diverse population
among women of child-bearing age.
Despite an observed association, there are several
limitations that warrant discussion. Although the IMS
dataset includes data for a sample of the commercially
insured from the 50 US states, this study population
may not be generalizable to other target populations,
including those with other private insurance and
Medicaid. Exposure ascertainment may be different
for DMPA and CHCs. DMPA exposure ascertainment
was based on procedure codes indicating administration
of the injection, while we relied on pharmacy claims for
CHC exposure ascertainment. The extent and impact of
possible exposure misclassiﬁcation of the CHC
deﬁnition remain unknown. Our analysis deﬁned units
of analysis (mean duration and proportion >2 years)
Published 2017. This article is a U.S. Government work and
is in the public domain in the USA.
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based on complete duration of use. Therefore, we were
unable to capture the impact of the boxed warning on
prescribing decision during use. Lastly, in our stratiﬁed
analysis by birth cohort, some women were excluded
because of their estimated age being less than 11 years
at index date. Future studies with date of birth
information should be conducted to conﬁrm the
observed ﬁndings by birth cohort.
CONCLUSION
Using an ITS design, we observed a modest decline in
the monthly mean duration of use and proportion of
patients who have episodes of use greater than
730 days for DMPA use immediately after addition
of the boxed warning. This change in utilization was
not observed among CHC users. In the stratiﬁed
analysis, we saw declines in the duration of use
>2 years in all age groups, except adolescents who
continue to use DMPA for longer than 2 years. Future
studies would need to conﬁrm these ﬁndings and the
effect of long-term DMPA use among adolescents.
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KEY POINTS
• The inclusion of the boxed warning in the US
prescription labeling in November 2004 resulted
in a decline in the duration of use for depot
medroxyprogesterone.
• Declines in the duration of use were observed in
all age groups, except for adolescents who
continue to use depot medroxyprogesterone for
longer than 2 years.
• The effect of long-term depot medroxyprogesterone
use among adolescents is warranted, since peak
bone accretion occurs during adolescence.
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